Patient Guide

Breast Implants: A 130-Year Safety History

UNE Plastic Surgery · Dr. Kim Uigeon, board-certified plastic surgeon · Published 2026-09-25 · Updated 2026-09-25

1. 1895–1940s: fat, paraffin, and silicone oil

The first attempt at breast enlargement dates to 1895, when the Czech surgeon Vincenz Czerny transplanted a lipoma from a patient’s back to the breast. The result was poor, but it was the starting point of the idea that breast shape could be made artificially. In 1899 came paraffin injection — liquid paraffin injected and set — and the outcome was grim: tumour formation, chronic inflammation, skin pigmentation, and in some cases migration to the lung, so it was effectively abandoned by the 1920s. A darker page was 1940s Japan and later California, where non-medical industrial liquid silicone oil was injected directly, producing silicone granulomas, lymph-node changes, chronic inflammation, and some deaths. Pangman’s polyvinyl-alcohol sponge (Ivalon, 1953) hardened and deformed and disappeared within a decade. Through the late 1950s, breast enlargement was a field where almost every attempt failed — and each failure taught how dangerous it is to inject foreign material into the breast.

2. 1962: Cronin and Gerow’s silicone implant

In 1961, two Houston surgeons, Thomas Cronin and Frank Gerow, worked with Dow Corning to develop a new device: a soft silicone shell holding a viscous silicone gel — the prototype of the modern breast implant. In spring 1962, at Jefferson Davis Hospital, a 30-year-old woman, Timmie Jean Lindsey, became the first patient to receive it. She kept those implants for the rest of her life; in a 2018 interview at age 86 she said there was no medical reason to remove them, so she left them — a living long-term follow-up of a first-generation implant, though a single case cannot be generalised. Dow Corning commercialised the device the following year.

3. 1970s–80s: the second-generation trap

The first-generation implant was safe but firm — patients complained it felt hard. The market wanted a more natural feel, so the second-generation implants of the 1970s took the opposite strategy: a thinner shell and a softer, runnier gel, marketed on “natural feel.” The result is remembered as a disaster:

• Ruptures surged — most second-generation implants examined by MRI showed rupture (Hölmich’s work).
• Gel bleed — silicone gel seeped microscopically through the shell.
• Silicone migration — silicone detected in lymph nodes, liver, and spleen.
• More capsular contracture, and reports of systemic symptoms — chronic fatigue, joint pain, cognitive complaints.

In December 1990 a CBS programme featured patients’ autoimmune symptoms, and public alarm grew. In December 1991 a California woman won a $7.4 million verdict against Dow Corning — the first time an implant safety defect was recognised in court — and over 250,000 lawsuits began to line up.

4. 1992: the FDA moratorium and Dow Corning’s bankruptcy

On 6 January 1992, FDA Commissioner David Kessler called for a voluntary moratorium on the sale and use of silicone gel breast implants. For the FDA to effectively ask that a 30-year-old device be withdrawn was rare. The stated reasons were three: after 30 years of use, safety data had not accumulated sufficiently; a link with autoimmune disease could not be excluded; and patients had not been given adequate information. Silicone gel was restricted to reconstruction and replacement, and only saline implants were allowed for general augmentation — a de facto ban in the U.S. from 1992 to 2006. Korea, Japan, and Europe did not follow the moratorium and kept using silicone gel, but the shock to the U.S. market hit the global industry. The biggest casualty was Dow Corning, which carried a $3.2 billion settlement in the class actions and filed for bankruptcy in May 1995.

5. 1992–2006: the saline era and the science

For 14 years saline implants held 99% of the U.S. market — a silicone shell with a saline fill, absorbed harmlessly on rupture, but with an immediate shape change, a water-bag feel, and visible rippling, especially unsuited to thin frames. Over the same years, large studies tested silicone gel’s safety, and the picture cleared: the 1999 Institute of Medicine report found no clear causal link between silicone gel implants and autoimmune disease (Bondurant et al., 1999),^[2] and Mayo Clinic and Harvard cohorts reached the same conclusion. A retrospective cohort of 395,543 female health professionals found a modest connective-tissue-disease relative risk of 1.24 (95% CI 1.08–1.41), but the authors flagged self-report bias and concluded a large risk was excluded (Hennekens et al., JAMA, 1996).^[1] So the concern about systemic autoimmune disease lacked firm scientific support, while local complications and reoperation over time became established fact — the core of later FDA labelling.

6. 2006 reapproval to the fifth-generation cohesive gel

On 17 November 2006, after 14 years, the FDA reapproved silicone gel implants — Mentor MemoryGel and Allergan (then Inamed) Natrelle first — under strict conditions: age 22+ for augmentation, mandatory informed consent, periodic imaging follow-up, annual manufacturer safety reports, and a 10-year follow-up cohort. (The 2006 imaging schedule was later revised in the 2020 guidance to a first ultrasound or MRI at 5–6 years, then every 2–3 years.) The “generations” became clear: first (1960s Cronin), second (1970s thin shell and soft gel), third (1980s reinforced shell), fourth (1990s cohesive gel), and around 2010 the fifth-generation highly cohesive gel — the “gummy bear,” which holds its shape and does not scatter even when cut or ruptured. Representative products include Allergan Natrelle 410 and Mentor MemoryShape; Motiva Ergonomix is widely used in Korea.

7. 2011–2020s: BIA-ALCL and the Allergan recall

BIA-ALCL (breast-implant-associated anaplastic large-cell lymphoma) is not a cancer of breast tissue but an immune-system lymphoma arising in the capsule around the implant, first flagged by the FDA in 2011. It is very rare, and frequency splits sharply by surface: the leading hypothesis is that a rough (textured) surface drives chronic inflammation and T-cell activation toward lymphoma, while it is almost absent with smooth surfaces. The decisive event was the July 2019 Allergan Biocell recall — the FDA cited a BIA-ALCL rate over six times that of other textured products and requested a voluntary recall, removing about 300,000 Biocell implants worldwide. The current standard is not to recommend preventive removal for asymptomatic patients, but to track with regular screening. Alongside came BII (Breast Implant Illness), a patient-led issue in which some report chronic fatigue, joint pain, brain fog, and autoimmune symptoms and point to the implant; in September 2020 the FDA added a boxed-warning item noting reported associations with systemic symptoms. BII remains a reported symptom complex without an established diagnostic definition.

8. 2021 onward: immunosurveillance and current issues

In 2021, Fracol et al. (Northwestern) added a new dimension: comparing serum from 104 healthy women (36 with long-term implants, 68 without), the implant group had significantly higher antibody responses to breast-cancer antigens (Mammaglobin-A, Mucin-1) (Plast Reconstr Surg, 2021).^[3] They tried to explain a background observation that cosmetic-implant patients have a lower breast-cancer risk (relative risk 0.63, 95% CI 0.56–0.71 — a figure they cited, not derived) as an immune response: a chronic low-grade immune reaction stimulating antibodies to breast antigens and strengthening cancer immunosurveillance. It is an interesting hypothesis — the same immune activation producing a negative outcome (BIA-ALCL, rough surfaces) and a positive one (immunosurveillance) — but it is still a hypothesis pending clinical confirmation. The issues that remain today: BIA-ALCL (rough surfaces; usually cured by capsulectomy when found), BII (in the boxed warning; diagnostic criteria and causation still being worked out), rare squamous cell carcinoma in the capsule (an FDA signal from 2022), the immunosurveillance hypothesis, and correcting the “replace every 10 years” myth — the FDA has never recommended uniform replacement.

Summary

• 130 years of learning safety. Paraffin, silicone oil, and the second-generation trap each taught what not to do; today’s standards are those lessons written down.
• 1992 was the turning point. The moratorium was called for insufficient data, not a proven danger; 14 years of study cleared silicone of a systemic-disease link while confirming local complications over time.
• Current issues are finer risk management. BIA-ALCL, BII, and rare new signals are tracked with regular screening — the point is not “are implants safe” but choosing a validated implant for the individual and managing it over time.

References

1. Hennekens CH, Lee IM, Cook NR, et al. Self-reported breast implants and connective-tissue diseases in female health professionals: a retrospective cohort study. JAMA. 1996;275(8):616–621. doi:10.1001/jama.1996.03530320040032.
2. Bondurant S, Ernster V, Herdman R, eds. Safety of Silicone Breast Implants. Institute of Medicine (US) Committee on the Safety of Silicone Breast Implants. Washington, DC: National Academies Press; 1999.
3. Fracol M, Shah N, Dolivo D, et al. Can breast implants induce breast cancer immunosurveillance? An analysis of antibody response to breast cancer antigen following implant placement. Plast Reconstr Surg. 2021;148(2):287–298. doi:10.1097/PRS.0000000000008165.